| GPS |
Table GPS-0. Nationwide surveys among the general population: Bibliographic references
|
table |
| GPS |
Table GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population
Part (i) Lifetime prevalence all adults
|
table |
| GPS |
Table GPS-1. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population
Part (ii) Survey methods
|
table |
| GPS |
Table GPS-2. Lifetime prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-3. Last year prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-4. Last year prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-5. Last month prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-6. Last month prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-7. Frequency of use of cannabis among all adults (aged 15 to 64 years) and young adults (aged 15 to 34 years) in nationwide surveys among the general population
Part (i) Frequency of use among all users in last month (percentage) — 2007 field trial
|
table |
| GPS |
Table GPS-7. Frequency of use of cannabis among all adults (aged 15 to 64 years old) and young adults (aged 15 to 34 years old) in nationwide surveys among the general population
Part (ii) Frequency of use among all users in last month (percentage) — 2004 field trial
|
table |
| GPS |
Table GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population.
Part (i) Lifetime prevalence all adults: last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population.
Part (ii) Survey methods: last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-9. Lifetime prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-10. Last year prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-11. Last year prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-12. Last month percentage prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-13. Last month prevalence of drug use among young adults (aged 15 to 34 years) in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-14. Lifetime prevalence of drug use among the 15–24 age group in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-15. Last year prevalence of drug use among the 15–24 age group in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-16. Last month prevalence of drug use among the 15–24 age group in nationwide surveys among the general population
|
table |
| GPS |
Table GPS-17. Lifetime prevalence of drug use among the age group of 15 to 24 years old in nationwide surveys among the general population. Last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-18. Last year prevalence of drug use among the 15–24 age group in nationwide surveys among the general population. Last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-19. Last month prevalence of drug use among the 15–24 age group in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards)
|
table |
| GPS |
Table GPS-121. Methodological information for nation-wide surveys among the general population
|
table |
| GPS |
Figure GPS-1. Last year prevalence of cannabis among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15- to 24-year-old age group, measured by national population surveys
|
figure |
| GPS |
Figure GPS-2. Continuation rates of cannabis (last year and last month use among lifetime users) in the general population, as measured by national surveys
Part (i) Lifetime prevalence all adults
|
figure |
| GPS |
Figure GPS-3. Last month prevalence of cannabis among the 15-to 24-year old age group, measured by national surveys
|
figure |
| GPS |
Figure GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys
Part (i) All countries
|
figure |
| GPS |
Figure GPS-4. Trends in last year prevalence of cannabis among young adults (aged 15 to 34), measured by national surveys
Part (ii) Countries with three or more surveys
|
figure |
| GPS |
Figure GPS-5. Last year prevalence of amphetamines among young adults aged 15 to 34 and 15 to 24, measured by population surveys
|
figure |
| GPS |
Figure GPS-6. Last year prevalence of amphetamines among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
|
figure |
| GPS |
Figure GPS-7. Last month prevalence of cannabis among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
|
figure |
| GPS |
Figure GPS-8. Trends in last year use of amphetamines among young adults (aged 15 to 34), measured by population surveys
Part (i) All countries
|
figure |
| GPS |
Figure GPS-8. Trends in last year use of amphetamines among young adults (aged 15 to 34), measured by population surveys
Part (ii) Countries with three or more surveys
|
figure |
| GPS |
Figure GPS-9. Last year prevalence of ecstasy among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group
Part (i) All Member States with available information
|
figure |
| GPS |
Figure GPS-9. Last year prevalence of ecstasy among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group
Part (ii) Males 15 to 24 in Member States with higher prevalence rates
|
figure |
| GPS |
Figure GPS-10. Last year prevalence of cannabis by age group in United Kingdom (E&W), measured by national population surveys
|
figure |
| GPS |
Figure GPS-11. Continuation rates of ecstasy (last year and last month use among lifetime users) in the general population, as measured by national surveys
|
figure |
| GPS |
Figure GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys — last survey available
Part (i) Last year prevalence in some of the EU-15 Member States
|
figure |
| GPS |
Figure GPS-12. Last year prevalence of cannabis by age group in some Member States, measured by national population surveys — last survey available
Part (ii) Last year prevalence in some new EU Member States
|
figure |
| GPS |
Figure GPS-13. Last year prevalence of cocaine among all young adults (aged 15 to 34 ) by gender, measured by national surveys
|
figure |
| GPS |
Figure GPS-14. Trends in last year prevalence of cocaine among young adults (aged 15 to 34), measured by population surveys
Part (i) All countries
|
figure |
| GPS |
Figure GPS-14. Trends in last year prevalence of cocaine among young adults (aged 15 to 34), measured by population surveys
Part (ii) Countries with three or more surveys
|
figure |
| GPS |
Figure GPS-15. Last year prevalence of cocaine use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
|
figure |
| GPS |
Figure GPS-16. Continuation rates of cocaine (last year and last month use among lifetime users) in the general population, measured by national surveys
|
figure |
| GPS |
Figure GPS-17. Last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34)
|
figure |
| GPS |
Figure GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34)
Part (i) Cannabis use — lifetime experience, last year and last month prevalence
|
figure |
| GPS |
Figure GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34)
Part (ii) Cocaine, amphetamines and ecstasy use — lifetime experience, last year and last month prevalence
|
figure |
| GPS |
Figure GPS-20. Figure GPS-20. Lifetime and last year prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA — last survey available for each country
|
figure |
| GPS |
Figure GPS-21. Trends in last year prevalence of ecstasy among young adults (aged 15 to 34), measured by population surveys
Part (i) All countries
|
figure |
| GPS |
Figure GPS-21. Trends in last year prevalence of ecstasy among young adults (aged 15 to 34), measured by population surveys
Part (ii) Countries with three or more surveys
|
figure |
| GPS |
Figure GPS-22. Continuation rates of amphetamines (last year and last month use among lifetime users) in the general population, as measured by national surveys
|
figure |
| GPS |
Figure GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (i) United Kingdom (E&W)
|
figure |
| GPS |
Figure GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (ii) Denmark
|
figure |
| GPS |
Figure GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (iii) Germany
|
figure |
| GPS |
Figure GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (iv) Spain
|
figure |
| GPS |
Figure GPS-23. Trends in last year prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States
Part (v) France
|
figure |
| EYE |
Table EYE-0. School surveys: Sources
|
table |
| EYE |
Table EYE-1. Recent school surveys (2003–06): percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years old
|
table |
| EYE |
Table EYE-2. Recent school surveys (2003–06): percentage lifetime prevalence (LTP) of psychoactive substance use and percentage last month prevalence (LMP) of cannabis among students aged 17 to 18 years
|
table |
| EYE |
Table EYE-3. School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years
|
table |
| EYE |
Table EYE-4. ESPAD 2003 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
Part (i) All students
|
table |
| EYE |
Table EYE-4. ESPAD 2003 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
Part (ii) Males
|
table |
| EYE |
Table EYE-4. ESPAD 2003 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
Part (iii) Females
|
table |
| EYE |
Table EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
Part (i) All students
|
table |
| EYE |
Table EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
Part (ii) Males
|
table |
| EYE |
Table EYE-5. ESPAD 2003 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
Part (iii) Females
|
table |
| EYE |
Table EYE-6. All ESPAD school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years
Part (i) All students
|
table |
| EYE |
Table EYE-6. All ESPAD school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years
Part (ii) Males
|
table |
| EYE |
Table EYE-6. All ESPAD school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years
Part (iii) Females
|
table |
| EYE |
Table EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
Part (i) All students
|
table |
| EYE |
Table EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
Part (ii) Males
|
table |
| EYE |
Table EYE-7. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
Part (iii) Females
|
table |
| EYE |
Table EYE-8. HBSC school surveys (2005/06): percentage lifetime prevalence of cannabis use among students aged 15–16 years old
|
table |
| EYE |
Table EYE-9. HBSC school surveys (2005/06): percentage of types of cannabis use during the last 12 months among students aged 15–16 years old
Part (i) All students
|
table |
| EYE |
Table EYE-9. HBSC school surveys (2005/06): percentage of types of cannabis use during the last 12 months among students aged 15–16 years old
Part (ii) Males
|
table |
| EYE |
Table EYE-9. HBSC school surveys (2005/06): percentage of types of cannabis use during the last 12 months among students aged 15–16 years old
Part (iii) Females
|
table |
| EYE |
Figure EYE-1. Comparison of polydrug use prevalence in the past month between all school students (aged 15–16) with those who use cannabis in 2003
|
figure |
| EYE |
Figure EYE-2. Comparison of polydrug use prevalence in the last month between all school students (aged 15–16) with those who used ecstasy in 2003
|
figure |
| EYE |
Figure EYE-4. Changes between 2001/02 and 2005/06 in prevalence of heavy cannabis use among school students aged 15–16
|
figure |
| PDU |
Table PDU-0. Prevalence of problem drug use at national and subnational level: bibliographic references
|
table |
| PDU |
Table PDU-1. Prevalence of problem drug use at national level: Summary Table, 2002–06, rate per 1000 aged 15–64
Part (i) Overall problem drug use
|
table |
| PDU |
Table PDU-1. Prevalence of problem drug use at national level: Summary Table, 2002–06, rate per 1000 aged 15–65
Part (ii) Injecting drug use
|
table |
| PDU |
Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2001 to 2006 (rate per 1 000 population aged 15 to 64): Combined estimates per country
Part (i) Estimated trends of overall problem drug use
|
table |
| PDU |
Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2001 to 2006 (rate per 1 000 population aged 15 to 64): Combined estimates per country
Part (ii) Estimated trends of problem opioid use
|
table |
| PDU |
Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2001 to 2006 (rate per 1 000 population aged 15 to 64): Combined estimates per country
Part (iii) Estimated trends of injecting drug use
|
table |
| PDU |
Table PDU-6. Estimated trends in the prevalence of problem and injecting drug use - 2001 to 2006 (rate per 1 000 population aged 15 to 64): Combined estimates per country
Part (iv) Estimated trends of problem stimulant use
|
table |
| PDU |
Table PDU-102. Prevalence of problem drug use at national level - full listing of studies
Part (i) Problem drug use
|
table |
| PDU |
Table PDU-102. Prevalence of problem drug use at national level - full listing of studies
Part (ii) Injecting drug use
|
table |
| PDU |
Table PDU-103. Prevalence of problem drug use at subnational level - full list of studies
Part (i) Problem drug users
|
table |
| PDU |
Table PDU-103. Prevalence of problem drug use at subnational level - full list of studies
Part (ii) Injecting drug users
|
table |
| PDU |
Table PDU-105. Studies of IDU providing information on sample structure by age and years injecting
Part (i) IDUs distribution by age
|
table |
| PDU |
Table PDU-105. Studies of IDU providing information on sample structure by age and years injecting
Part (ii) IDUs distribution by years injecting
|
table |
| PDU |
Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2002 to 2006 — last study available
Part (i) Estimates of overall problem drug use
|
figure |
| PDU |
Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2002 to 2006 – last study available
Part (ii) Estimates for problem opioid use
|
figure |
| PDU |
Figure PDU-2. Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), 2002 to 2006 — last study available
|
figure |
| PDU |
Figure PDU-3. Percentage of new and of young injectors reported in samples of injecting drug users tested for HIV or HCV, studies from 2004 to 2006
|
figure |
| DUP |
Table DUP-0. Prevalence of drug use among prisoners — Sources and bibliographic references
|
table |
| DUP |
Table DUP-1. Prevalence of lifetime drug use among prisoners, 2000–06
|
table |
| DUP |
Table DUP-2. Prevalence of lifetime injecting drug use among prisoners, 2000–06
|
table |
| DUP |
Table DUP-3. Prevalence of drug use within prison among prisoners, 2000–07
|
table |
| DUP |
Table DUP-4. Prevalence of injecting drug use within prison among prisoners, 2000–07
|
table |
| DUP |
Table DUP-105. Prevalence (percentage) of drug use among prisoners in EU Member States and Norway – full listing of studies
|
table |
| INF |
Table INF-0. Bibliographic references
|
table |
| INF |
Table INF-1. Prevalence of HIV infection among injecting drug users in the EU, 2006 or most recent year available — Summary table by country
|
table |
| INF |
Table INF-2. Prevalence of HCV antibody among injecting drug users in the EU, 2006 or most recent year available — Summary table by country
|
table |
| INF |
Table INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU, 2006 or most recent year available — Summary table by country
|
table |
| INF |
Table INF-18. Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 2001 to 2006, samples with average prevalence above 5 %
|
table |
| INF |
Table INF-19. Trends in HCV antibody prevalence in national and subnational samples of injecting drug users 2001 to 2006, countries with average prevalence above 50 %.
|
table |
| INF |
Table INF-104. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2006, (a) cases per million population, (b) number of cases and (c) population sizes
|
table |
| INF |
Table INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all cases with known risk factor
|
table |
| INF |
Table INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all notified cases with known risk factor
|
table |
| INF |
Table INF-107. Incidence studies of hepatitis C virus infection among injecting drug users in the EU
|
table |
| INF |
Table INF-108. Prevalence of HIV infection (percentage) among injecting drug users, 1991 to 2007
|
table |
| INF |
Table INF-109. Prevalence of HIV infection (percentage) among injecting drug users under age 25, 1991 to 2007
|
table |
| INF |
Table INF-110. Prevalence of HIV infection (percentage) among new injecting drug users (injecting less than 2 years), 1991 to 2006
|
table |
| INF |
Table INF-111. Prevalence of hepatitis C infection (percentage) among injecting drug users, 1991 to 2007
|
table |
| INF |
Table INF-112. Prevalence of hepatitis C infection (percentage) among injecting drug users under age 25, 1991 to 2007
|
table |
| INF |
Table INF-113. Prevalence of hepatitis C infection (percentage) among new injecting drug users (injecting less than 2 years), 1991 to 2006
|
table |
| INF |
Table INF-114. Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users, 1991 to 2006
|
table |
| INF |
Table INF-115. Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users, 1991 to 2006
|
table |
| INF |
Table INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006
Part (i) Prevalence of HIV infection (percentage) among injecting drug users in prison
|
table |
| INF |
Table INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006
Part (ii) Prevalence of hepatitis C infection (percentage) among injecting drug users in prison
|
table |
| INF |
Table INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006
Part (iii) Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users in prison
|
table |
| INF |
Table INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006
Part (iv) Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users in prison
|
table |
| DRD |
Table DRD-0. Drug-induced deaths recorded in EU Member States according to national definitions: sources and bibliographic references
|
table |
| DRD |
Table DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions
Part (i) Demographic characteristics, 2006 or last year with available information
|
table |
| DRD |
Table DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions
Part (ii) Numbers of drug-induced deaths and toxicology, 2006 or last year with available information
|
table |
| DRD |
Table DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions
Part (iii) Demographic characteristics and toxicology, 1990 or closest year with available information
|
table |
| DRD |
Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
Part (i) Total drug-induced deaths, 1995 to 2006
|
table |
| DRD |
Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
Part (ii) Male drug-induced deaths, 1995 to 2006
|
table |
| DRD |
Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
Part (iii) Female drug-induced deaths, 1995 to 2006
|
table |
| DRD |
Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
Part (iv) Total drug-induced deaths under the age of 25 years, 1995 to 2006
|
table |
| DRD |
Table DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions
Part (v) Totals and indexes, 1995 to 2006
|
table |
| DRD |
Table DRD-3. Number of drug-induced deaths recorded in EU Member States and Norway according to EMCDDA standard definition 'Selection B', 1995 to 2006
|
table |
| DRD |
Table DRD-4. Number of drug-induced deaths recorded in EU Member States according to EMCDDA standard definition 'Selection D', 1995 to 2006
|
table |
| DRD |
Table DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males)
Part (i) Population mortality rates, 2006 or last year with available information
|
table |
| DRD |
Table DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males)
Part (ii) Proportional mortality due to drug-induced deaths, 2006 or last year with available information
|
table |
| DRD |
Table DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males)
Part (iii) Estimated mortality (numbers and population rates) due to AIDS attributable to injection drug use
|
table |
| DRD |
Table DRD-106. Methodological features of drug-induced deaths reported by Reitox national focal points (Based on national definitions – Reitox Standard Table 5).
|
table |
| DRD |
Table DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions
Part (i) Total drug-induced deaths, 1985 to 2006
|
table |
| DRD |
Table DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions
Part (ii) Totals and indexes, 1985 to 2006
|
table |
| DRD |
Table DRD-108. Drug-induced deaths: Detailed qualitative national information on deaths due to specific substances in EU Member States (2007 National reports)
|
table |
| DRD |
Figure DRD-1. Proportion of drug-induced deaths that show presence of opioids for the most recent year reported
|
figure |
| DRD |
Figure DRD-2. Proportion of drug-induced deaths occurring under the age of 25 years in 2004
|
figure |
| DRD |
Figure DRD-3. Trends in mean age of drug-induced deaths in some of the EU-15 Member States, 1990 to 2006
|
figure |
| DRD |
Figure DRD-4. Trends in mean age of drug-induced deaths in some new EU Member States, 1990 to 2006
|
figure |
| DRD |
Figure DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25
Part (i) Indexed trend in the EU-15 Member States and Norway 1990–2005
|
figure |
| DRD |
Figure DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25
Part (ii) Indexed trend in the new Member States, 1990–2005
|
figure |
| DRD |
Figure DRD-6. Indexed overall trends for males and females in drug-induced deaths in the EU-15 Member States and Norway, 1990 to 2005
|
figure |
| DRD |
Figure DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries
Part (i) Mortality rates among all adults (15 to 64 years) due to drug-related deaths and 95 % confidence intervals for last year available
|
figure |
| DRD |
Figure DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries
Part (ii) Mortality rates among all adults (15 to 64 years) due to drug-related deaths and estimated mortality rates due to Aids attributable to injection drug use
|
figure |
| DRD |
Figure DRD-8. Indexed long term trend in drug-induced deaths in the EU 15 Member States and Norway, 1985 to 2005
|
figure |
| DRD |
Figure DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2006 (three-year moving average)
Part (i) Some EU Member States and Norway, 1990 to 2006
|
figure |
| DRD |
Figure DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2006 (three-year moving average)
Part (ii) Some EU Member States, 1990 to 2006
|
figure |
| DRD |
Figure DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2006 (three-year moving average)
Part (iii) Some EU countries, 1990 to 2006
|
figure |
| DRD |
Figure DRD-10. Mean age of drug-induced deaths in EU Member States, last year with available data
|
figure |
| DRD |
Figure DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole
Part (i) Index in some Member States, 1985 to 2006
|
figure |
| DRD |
Figure DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole
Part (ii) Index in some Member States, 1985 to 2006
|
figure |
| DRD |
Figure DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole
Part (iii) Index in some Member States, 1985 to 2006
|
figure |
| DRD |
Figure DRD-12. Proportional change in drug-induced deaths in the EU Member States
Part (i) Changes between 2000 and 2003
|
figure |
| DRD |
Figure DRD-12. Proportional change in drug-induced deaths in the EU Member States
Part (ii) Changes between 2003 and 2004/5
|
figure |
| DRD |
Figure DRD-12. Proportional change in drug-induced deaths in the EU Member States
Part (iii) Changes between 2001 and 2005/6
|
figure |
| DRD |
Figure DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions
Part (i) EU-15 Member States and Norway 1990–2005
|
figure |
| DRD |
Figure DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions
Part (ii) New Member States, 1990–2005
|
figure |
| DLO |
Table DLO-1. Drug law offences 1995 to 2006
Part (i) Number of reports
|
table |
| DLO |
Table DLO-1. Drug law offences 1995 to 2006
Part (ii) Methodological notes
|
table |
| DLO |
Table DLO-2. Offence types in reports for drug law offences
Part (i) Percentage of all reports for drug law offences
|
table |
| DLO |
Table DLO-2. Offence types in reports for drug law offences
Part (ii) Methodological notes
|
table |
| DLO |
Table DLO-3. Drug types in reports for drug law offences
Part (i) Percentage of all reports for drug law offences
|
table |
| DLO |
Table DLO-3. Drug types in reports for drug law offences
Part (ii) Methodological notes
|
table |
| DLO |
Table DLO-4. Drug law offences related to drug use or possession for use, 2000 to 2006
Part (i) Number and percentage
|
table |
| DLO |
Table DLO-4. Drug law offences related to drug use or possession for use, 2000 to 2006
Part (ii) Methodological notes
|
table |
| DLO |
Table DLO-5. Drug law offences related to drug trafficking, 2000 to 2006
Part (i) Number and percentage
|
table |
| DLO |
Table DLO-5. Drug law offences related to drug trafficking, 2000 to 2006
Part (ii) Methodological notes
|
table |
| DLO |
Table DLO-6. Cannabis-related offences, 2000 to 2006
Part (i) Number and percentage of all drug law offences
|
table |
| DLO |
Table DLO-6. Cannabis-related offences, 2000 to 2006
Part (ii) Methodological notes
|
table |
| DLO |
Table DLO-7. Heroin-related offences, 2000 to 2006
Part (i) Number and percentage of all drug law offences
|
table |
| DLO |
Table DLO-7. Heroin-related offences, 2000 to 2006
Part (ii) Methodological notes
|
table |
| DLO |
Table DLO-8. Cocaine-related offences, 2000 to 2006
Part (i) Number and percentage of all drug law offences
|
table |
| DLO |
Table DLO-8. Cocaine-related offences, 2000 to 2006
Part (ii) Methodological notes
|
table |
| DLO |
Table DLO-109. Number of reports for drug law offences 1985 to 2006
Part (i) Number of reports
|
table |
| DLO |
Table DLO-109. Number of reports for drug law offences 1985 to 2006
Part (ii) Methodological notes
|
table |
| DLO |
Figure DLO-1. Drug law offences in Europe, 2001–06
Part (i) EU-15 Member States and Norway
|
figure |
| DLO |
Figure DLO-1. Drug law offences in Europe, 2001–06
Part (ii) Other EU Member States, Croatia and Turkey
|
figure |
| DLO |
Figure DLO-2. Indexed trends in reports for drug-related offences by broad type of offence in the EU Member States 2001–06
|
figure |
| DLO |
Figure DLO-3. Indexed trends in reports for drug law offences by type of drug in the EU Member States 2001–06
|
figure |
| DLO |
Figure DLO-4. Indexed trends in reports for offences related to drug use or possession for use in the EU Member States 2001–06
|
figure |
| DLO |
Figure DLO-5. Cannabis-related offences in Europe, 2001–06
Part (i) EU-15 Member States and Norway
|
figure |
| DLO |
Figure DLO-5. Cannabis-related offences in Europe, 2001–06
Part (ii) Other EU Member States, Croatia and Turkey
|
figure |
| DLO |
Figure DLO-6. Cocaine-related offences in Europe, 2001–06
Part (i) EU-15 Member States and Norway
|
figure |
| DLO |
Figure DLO-6. Cocaine-related offences in Europe, 2001–06
Part (ii) Other EU Member States, Croatia and Turkey
|
figure |
| DLO |
Figure DLO-7. Heroin-related offences in Europe, 2001–06
Part (i) EU-15 Member States and Norway
|
figure |
| DLO |
Figure DLO-7. Heroin-related offences in Europe, 2001–06
Part (ii) Other EU Member States, Croatia and Turkey
|
figure |
| TDI |
Table TDI-1. Data sources for data on clients entering treatment in 2006
|
table |
| TDI |
Table TDI-2. Trends in the number of clients entering treatment and the number of reporting treatment centres, 1996 to 2006
Part (i) Total numbers of new clients entering treatment
|
table |
| TDI |
Table TDI-2. Trends in the number of clients entering treatment and the number of reporting treatment centres, 1996 to 2006
Part (ii) Total numbers of all clients entering treatment
|
table |
| TDI |
Table TDI-2. Trends in the number of clients entering treatment and the number of reporting treatment centres, 1996 to 2006
Part (iii) Numbers of treatment units covered for reporting clients entering treatment
|
table |
| TDI |
Table TDI-2. Trends in the number of clients entering treatment and the number of reporting treatment centres, 1996 to 2006
Part (iv) Types of units covered for reporting clients entering treatment
|
table |
| TDI |
Table TDI-3. Trend of new clients entering treatment by primary drug used, 1993 to 2006
Part (i) Percentage of new clients using heroin
|
table |
| TDI |
Table TDI-3. Trend of new clients entering treatment by primary drug used, 1993 to 2006
Part (ii) Percentage of new clients using cocaine
|
table |
| TDI |
Table TDI-3. Trend of new clients entering treatment by primary drug used, 1993 to 2006
Part (iii) Percentage of new clients using stimulants (amphetamines and MDMA)
|
table |
| TDI |
Table TDI-3. Trend of new clients entering treatment by primary drug used, 1993 to 2006
Part (iv) Percentage of new clients using cannabis
|
table |
| TDI |
Table TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available
Part (i) Demographics of new clients entering treatment
|
table |
| TDI |
Table TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available
Part (ii) Primary drug type used (percent of new clients using) and of those, the percent injecting it
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available
Part (i) Demographics of all clients entering treatment
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available
Part (ii) Primary drug type used by clients (percentage of all clients) and of those, the percentage injecting the drug
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available
Part (iii) Demographics of all men entering treatment
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available
Part (iv) Demographics of all women entering treatment
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available
Part (v) Primary drug type used by male clients (percentage of all male clients)
|
table |
| TDI |
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2006 or most recent year available
Part (vi) Primary drug type used by female clients (percentage of all female clients)
|
table |
| TDI |
Table TDI-6. Incidence of treatment demands for drug use: new clients entering treatment in 2006 (rate per 100 000 population)
|
table |
| TDI |
Table TDI-7. Data coverage in 2006 for countries supplying data
Part (i) Number of new and all clients entering treatment by type of treatment centre
|
table |
| TDI |
Table TDI-7. Data coverage in 2006 for countries supplying data
Part (ii) Number and type of treatment centre
|
table |
| TDI |
Table TDI-8. Amphetamines, ecstasy and other non-cocaine stimulants: primary use among new and all clients entering treatment in 2006 for countries supplying data
Part (i) All clients with primary use of stimulants other than cocaine in treatment centres reported for the country
|
table |
| TDI |
Table TDI-8. Amphetamines, ecstasy and other non-cocaine stimulants: primary use among new and all clients entering treatment in 2006 for countries supplying data
Part (ii) New clients with primary use of stimulants other than cocaine in treatment centres reported for the country
|
table |
| TDI |
Table TDI-9. Mean age and gender distribution among new and all clients entering outpatient treatment in 2006
|
table |
| TDI |
Table TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006
Part (i) Percentage distribution of new outpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006
Part (ii) Percentage distribution of new outpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006
Part (iii) Percentage distribution of all outpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006
Part (iv) Percentage distribution of all outpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006
Part (v) Percentage distribution of new inpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006
Part (vi) Percentage distribution of new inpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006
Part (vii) Percentage distribution of all inpatient clients by age group for each primary drug
|
table |
| TDI |
Table TDI-10. Age distribution by primary drug of clients entering treatment — EU overall summary in 2006
Part (viii) Percentage distribution of all inpatient clients by primary drug for each age group
|
table |
| TDI |
Table TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006
Part (i) Percentage distribution of new outpatient clients by age at first use for each primary drug
|
table |
| TDI |
Table TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006
Part (ii) Percentage distribution of new outpatient clients by primary drug for age at first use
|
table |
| TDI |
Table TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006
Part (iii) Percentage distribution of all outpatient clients by age at first use for each primary drug
|
table |
| TDI |
Table TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006
Part (iv) Percentage distribution of all outpatient clients by primary drug for age at first use
|
table |
| TDI |
Table TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006
Part (v) Percentage distribution of new inpatient clients by age at first use for each primary drug
|
table |
| TDI |
Table TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006
Part (vi) Percentage distribution of new inpatient clients by primary drug for age at first use
|
table |
| TDI |
Table TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006
Part (vii) Percentage distribution of all inpatient clients by age at first use for each primary drug
|
table |
| TDI |
Table TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU overall summary in 2006
Part (viii) Percentage distribution of all inpatient clients by primary drug for age at first use
|
table |
| TDI |
Table TDI-12. Percentage distribution of educational level for clients entering treatment in 2006
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-12. Percentage distribution of educational level for clients entering treatment in 2006
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-12. Percentage distribution of educational level for clients entering treatment in 2006
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-12. Percentage distribution of educational level for clients entering treatment in 2006
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-13. Percentage distribution of labour status for clients entering treatment in 2006
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-13. Percentage distribution of labour status for clients entering treatment in 2006
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-13. Percentage distribution of labour status for clients entering treatment in 2006
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-13. Percentage distribution of labour status for clients entering treatment in 2006
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-14. Percentage distribution of accommodation arrangements (persons with whom the client is living) of clients entering treatment in 2006
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-14. Percentage distribution of accommodation arrangements (persons with whom the client is living) of clients entering treatment in 2006
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-14. Percentage distribution of accommodation arrangements (persons with whom the client is living) of clients entering treatment in 2006
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-14. Percentage distribution of accommodation arrangements (persons with whom the client is living) of clients entering treatment in 2006
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-15. Percentage distribution of living conditions for clients entering treatment in 2006
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-15. Percentage distribution of living conditions for clients entering treatment in 2006
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-15. Percentage distribution of living conditions for clients entering treatment in 2006
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-15. Percentage distribution of living conditions for clients entering treatment in 2006
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-16. Percentage distribution of source of referral for new clients entering outpatient and inpatient treatment in 2006
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-16. Percentage distribution of source of referral for new clients entering outpatient and inpatient treatment in 2006
Part (ii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006
Part (i) Percentage distribution of route of administration amongst new clients with opioids as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006
Part (ii) Percentage distribution of route of administration amongst new clients with cocaine (HCl and crack) as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006
Part (iii) Percentage distribution of route of administration amongst new clients with stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006
Part (iv) Percentage distribution of route of administration amongst new clients with hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006
Part (v) Percentage distribution of route of administration amongst all clients with opioids as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006
Part (vi) Percentage distribution of route of administration amongst all clients with cocaine (HCl and crack) as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006
Part (vii) Percentage distribution of route of administration amongst all clients with stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-17. Route of administration of primary drug among new and all outpatient clients in 2006
Part (viii) Percentage distribution of route of administration amongst all clients with hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2006
Part (i) Percentage distribution amongst new outpatient clients
|
table |
| TDI |
Table TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2006
Part (ii) Percentage distribution amongst all outpatient clients
|
table |
| TDI |
Table TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2006
Part (iii) Percentage distribution amongst new inpatient clients
|
table |
| TDI |
Table TDI-18. Frequency of use of primary drug among new and all outpatient and inpatient clients in 2006
Part (iv) Percentage distribution amongst all inpatient clients
|
table |
| TDI |
Table TDI-19. Percentage distribution of primary drug among new and all clients entering outpatient and inpatient treatment in 2006
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-19. Percentage distribution of primary drug among new and all clients entering outpatient and inpatient treatment in 2006
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-19. Percentage distribution of primary drug among new and all clients entering outpatient and inpatient treatment in 2006
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-19. Percentage distribution of primary drug among new and all clients entering outpatient and inpatient treatment in 2006
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2006 and in the general population
Part (i) New clients entering outpatient treatment
|
table |
| TDI |
Table TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2006 and in the general population
Part (ii) All clients entering outpatient treatment
|
table |
| TDI |
Table TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2006 and in the general population
Part (iii) New clients entering inpatient treatment
|
table |
| TDI |
Table TDI-20. Unemployment rates among new and all clients entering outpatient and inpatient treatment in 2006 and in the general population
Part (iv) All clients entering inpatient treatment
|
table |
| TDI |
Table TDI-21. Gender ratio by primary drug — ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2006
Part (i) Ratio of males to females among new clients entering outpatient treatment
|
table |
| TDI |
Table TDI-21. Gender ratio by primary drug — ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2006
Part (ii) Ratio of males to females among all clients entering outpatient treatment
|
table |
| TDI |
Table TDI-21. Gender ratio by primary drug — ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2006
Part (iii) Ratio of males to females among new clients entering inpatient treatment
|
table |
| TDI |
Table TDI-21. Gender ratio by primary drug — ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2006
Part (iv) Ratio of males to females among all clients entering inpatient treatment
|
table |
| TDI |
Table TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2006: average for those EU countries supplying data
Part (i) Outpatient centres
|
table |
| TDI |
Table TDI-22. Secondary drugs: number of citations by all clients in outpatient and inpatient centres in 2006: average for those EU countries supplying data
Part (ii) Inpatient centres
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type
Part (i) Percentage distribution of secondary drug by primary drug for the EU overall
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type
Part (ii) All clients with opioids as primary drug type: number of episodes reporting the stated drug as secondary
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type
Part (iii) All clients with cocaine as primary drug type: number of episodes reporting the stated drug as secondary
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type
Part (iv) All clients with cannabis as primary drug: number of episodes reporting the stated drug as secondary
|
table |
| TDI |
Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type
Part (v) All clients with stimulants other than cocaine as primary drug type: number of episodes reporting the stated drug as secondary
|
table |
| TDI |
Table TDI-24. Percentage of clients by type of treatment centres and by primary drug for all and new clients entering treatment in 2006 (outpatient, inpatient and other types of treatment centres)
Part (i) All clients
|
table |
| TDI |
Table TDI-24. Percentage of outpatient and inpatient clients by primary drug for all and new clients entering treatment in 2006
Part (ii) New clients
|
table |
| TDI |
Table TDI-25. Percentage distribution of age by gender among all clients entering outpatient treatment with primary drug: opioids, cocaine, stimulants and cannabis in 2006 for countries supplying data
|
table |
| TDI |
Table TDI-32. Mean age by gender by primary drug among all clients entering outpatient and inpatient treatment in 2006
Part (i) Outpatient clients
|
table |
| TDI |
Table TDI-32. Mean age by gender by primary drug among all clients entering outpatient and inpatient treatment in 2006
Part (ii) Inpatient clients
|
table |
| TDI |
Table TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering outpatient and inpatient treatment in 2006
Part (i) Outpatient treatment centres
|
table |
| TDI |
Table TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering outpatient and inpatient treatment in 2006
Part (ii) Inpatient treatment centres
|
table |
| TDI |
Table TDI-34. Outpatient and inpatient treatment centres and treatment units in prison: number of all clients entering treatment and number and percentages of units covered in four countries supplying data in 2006
|
table |
| TDI |
Table TDI-35. Outpatient and inpatient treatment centres and treatment units in prison: percentage distribution of all clients by primary drug in four countries supplying data in 2006
|
table |
| TDI |
Table TDI-36. Trends in primary amphetamines use among new clients entering treatment between 2001 and 2006 in four countries
|
table |
| TDI |
Table TDI-37. Amphetamines and ecstasy clients entering drug treatment in 2006
Part (i) Outpatient and inpatient clients entering treatment for primary amphetamines and ecstasy use in 2006
|
table |
| TDI |
Table TDI-37. Amphetamines and ecstasy clients entering drug treatment in 2006
Part (ii) Mean age and gender ratio among primary amphetamines or ecstasy clients entering treatment in 2006
|
table |
| TDI |
Table TDI-37. Amphetamines and ecstasy clients entering drug treatment in 2006
Part (iii) Secondary drugs among outpatient and inpatient clients entering treatment for primary amphetamines and ecstasy use (number of citations)
|
table |
| TDI |
Table TDI-38. All clients in treatment (treatment prevalence) for primary use of amphetamines, ecstasy and other stimulants (other than cocaine) in countries reporting in 2006: demographics and patterns of drug use
|
table |
| TDI |
Table TDI-39. Treatment prevalence in 2006 in nine countries: percentage distribution of all treatment clients by primary drug at treatment entry (first treatment incidence, total treatment incidence, total treatment prevalence)
|
table |
| TDI |
Table TDI-40. Treatment Prevalence in 2006: proportion of injectors by primary drug (excluding cannabis) among treated clients in 2006 in nine countries (first treatment incidence, total treatment incidence, total treatment prevalence)
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(i) Number of clients using opioids as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(ii) Number of clients using cocaine (HCl and 'crack') as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(iv) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (v) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-102. New clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(i) Number of clients using opioids as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(ii) Number of clients using cocaine (HCl and 'crack') as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(iv) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (v) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-103. All clients entering outpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(i) Number of clients using opioids as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(ii) Number of clients using cocaine (HCl and 'crack') as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(iv) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (v) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-104. New clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(i) Number of clients using opioids as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(ii) Number of clients using cocaine (HCl and 'crack') as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part(iv) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (v) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-105. All clients entering inpatient treatment: age and primary drug at treatment in 2006 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (i) Number of clients using opiates as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (ii) Number of clients using cocaine as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (iv) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (v) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-106. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (i) Number of clients using opiates as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (ii) Number of clients using cocaine as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (iv) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (v) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-107. All clients entering outpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (i) Number of clients using opioids as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (ii) Number of clients using cocaine as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (iv) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (v) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (vi) Number of clients using volatile/inhalants as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-108. New clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (i) Number of clients using opiates as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (ii) Number of clients using cocaine as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (iii) Number of clients using stimulants (other than cocaine) as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (iv) Number of clients using hypnotics and sedatives as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (v) Number of clients using hallucinogens as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (vi) Number of clients using volatile inhalants as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (vii) Number of clients using cannabis as primary drug
|
table |
| TDI |
Table TDI-109. All clients entering inpatient treatment: age at first use of primary drug at treatment in 2006 for those countries supplying data
Part (viii) Number of clients using other drugs as primary drugs
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006
Part (i) Percentage distribution amongst new clients with opioids as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006
Part (ii) Percentage distribution amongst all clients with opioids as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006
Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006
Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006
Part (v) Percentage distribution amongst new clients with amphetamines and MDMA as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006
Part (vi) Percentage distribution amongst all clients with amphetamines and MDMA as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006
Part (vii) Percentage distribution amongst new clients with cocaine as primary drug
|
table |
| TDI |
Table TDI-111. Frequency of use of primary drug among new and all outpatient clients in 2006
Part (viii) Percentage distribution amongst all clients with cocaine as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006
Part (i) Percentage distribution amongst new clients with opioids as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006
Part (ii) Percentage distribution amongst all clients with opioids as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006
Part (iii) Percentage distribution amongst new clients with cannabis as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006
Part (iv) Percentage distribution amongst all clients with cannabis as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006
Part (v) Percentage distribution amongst new clients with amphetamines and MDMA as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006
Part (vi) Percentage distribution amongst all clients with amphetamines and MDMA as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006
Part (vii) Percentage distribution amongst new clients with cocaine as primary drug
|
table |
| TDI |
Table TDI-112. Frequency of use of primary drug among new and all inpatient clients in 2006
Part (viii) Percentage distribution amongst all clients with cocaine as primary drug
|
table |
| TDI |
Table TDI-113. All clients entering treatment for opioids by type of opioid misused for countries supplying data in 2006
|
table |
| TDI |
Table TDI-114. Primary opioids distribution (percent) among all clients entering treatment by type of treatment centre in three countries supplying data in 2006
|
table |
| TDI |
Table TDI-115. Primary cocaine use – HCL and Crack – among new and all clients entering outpatient drug treatment in 2006 for countries supplying data
Part (i) All clients
|
table |
| TDI |
Table TDI-115. Primary cocaine use – HCL and Crack – among new and all clients entering outpatient drug treatment in 2006 for countries supplying data
Part (ii) New clients
|
table |
| TDI |
Figure TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2002 to 2006
Part (i) Percentage distribution by primary drug
|
figure |
| TDI |
Figure TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2002 to 2006
Part (ii) Numbers of clients by primary drug
|
figure |
| TDI |
Figure TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2006 in 24 EU Member States
Part (i) New clients
|
figure |
| TDI |
Figure TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2006 in 24 EU Member States
Part (ii) All clients
|
figure |
| TDI |
Figure TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2002 to 2006
Part (i) Percentage distribution by primary drug
|
figure |
| TDI |
Figure TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2002 to 2006
Part (ii) Numbers of clients by primary drug
|
figure |
| TDI |
Figure TDI-6. New and all outpatient clients by age group in 2006 for those countries supplying data
|
figure |
| TDI |
Figure TDI-11. Clients entering first treatment, all clients entering treatment, total clients in treatment, summary of nine EU countries reporting in 2006
Part (i) Number of clients in treatment
|
figure |
| TDI |
Figure TDI-11. Clients entering first treatment, all clients entering treatment, total clients in treatment, summary of nine EU countries reporting in 2006
Part (ii) Percentage of clients in treatment with opioids, cannabis or other drugs as primary drugs
|
figure |
| HSR |
Table HSR-1. Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT) and heroin-assisted treatment, including trials
|
table |
| HSR |
Table HSR-2. Legal framework and practice of substitution treatment initiation
|
table |
| HSR |
Table HSR-3. Estimated number of clients in methadone treatment and of clients receiving any opioid substitution
Part (i): Estimates of clients in methadone treatment or opioid substitution in EU-27, Croatia, Turkey and Norway, 2005 and 2006
|
table |
| HSR |
Table HSR-3. Estimated number of clients in methadone treatment and of clients receiving any opioid substitution
Part (ii) Methodological notes for EU-27, Norway and Croatia, 2005 and 2006
|
table |
| HSR |
Table HSR-4. Year of introduction of needle and syringe programmes and types of programmes available in 2006
|
table |
| HSR |
Table HSR-5. Number of syringes provided through needle and syringe programmes 2005–06
|
table |
| HSR |
Figure HSR-1. Number of opioid maintenance treatment clients as rate per 100 of the estimated number of problem opioid users, 2005–06
|
figure |
| SZR |
Table SZR-1. Number of cannabis resin seizures, 1995 to 2006
|
table |
| SZR |
Table SZR-2. Quantities (kg) of cannabis resin seized, 1995 to 2006
|
table |
| SZR |
Table SZR-3. Number of herbal cannabis seizures, 1995 to 2006
|
table |
| SZR |
Table SZR-4. Quantities (kg) of herbal cannabis seized, 1995 to 2006
|
table |
| SZR |
Table SZR-5. Number of seizures of cannabis plants, 1995 to 2006
|
table |
| SZR |
Table SZR-6. Quantities (number of plants) of cannabis plants seized, 1995 to 2006
|
table |
| SZR |
Table SZR-7. Number of heroin seizures 1995 to 2006
|
table |
| SZR |
Table SZR-8. Quantities (kg) of heroin seized 1995 to 2006
|
table |
| SZR |
Table SZR-9. Number of cocaine seizures 1995 to 2006
|
table |
| SZR |
Table SZR-10. Quantities (kg) of cocaine seized 1995 to 2006
|
table |
| SZR |
Table SZR-11. Number of amphetamine seizures 1995 to 2006
|
table |
| SZR |
Table SZR-12. Quantities (kg) of amphetamine seized 1995 to 2006
|
table |
| SZR |
Table SZR-13. Number of ecstasy seizures 1995 to 2006
|
table |
| SZR |
Table SZR-14. Quantities (tablets) of ecstasy seized 1995 to 2006
|
table |
| SZR |
Table SZR-15. Number of LSD seizures 1995 to 2006
|
table |
| SZR |
Table SZR-16. Quantities (units) of LSD seized 1995 to 2006
|
table |
| SZR |
Table SZR-17. Number of Methamphetamine seizures. 2001 to 2006
|
table |
| SZR |
Table SZR-18. Quantities (kg) of Methamphetamine seized — 2001 to 2006
|
table |
| PPP |
Table PPP-1. Price of cannabis products at retail level, 2006
Part (i) Minimum, maximum, mean and modal (typical) price in euros
|
table |
| PPP |
Table PPP-1. Price of cannabis products at retail level, 2006
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-2. Price of heroin at retail level, 2006
Part (i) Minimum, maximum, mean and modal (typical) price in euros
|
table |
| PPP |
Table PPP-2. Price of heroin at retail level, 2006
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-3. Price of cocaine products at retail level, 2006
Part (i) Minimum, maximum, mean and modal (typical) price in euros
|
table |
| PPP |
Table PPP-3. Price of cocaine products at retail level, 2006
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-4. Price of synthetic drugs at retail level, 2006
Part (i) Minimum, maximum, mean and modal (typical) price in euros
|
table |
| PPP |
Table PPP-4. Price of synthetic drugs at retail level, 2006
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-5. Potency of cannabis products at retail level, 2006
Part (i) Minimum, maximum, mean and modal (typical) potency recorded, measured as percentage of THC content
|
table |
| PPP |
Table PPP-5. Potency of cannabis products at retail level, 2006
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-5. Potency of cannabis products at retail level, 2006
Part (iii) Sampling frame / Type of study
|
table |
| PPP |
Table PPP-6. Purity of heroin at retail level, 2006
Part (i) Minimum, maximum, mean and modal (typical) purity recorded (percentage)
|
table |
| PPP |
Table PPP-6. Purity of heroin at retail level, 2006
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-6. Purity of heroin at retail level, 2006
Part (iii) Sampling frame / Type of study
|
table |
| PPP |
Table PPP-7. Purity of cocaine products at retail level, 2006
Part (i) Minimum, maximum, mean and modal (typical) purity recorded (percentage)
|
table |
| PPP |
Table PPP-7. Purity of cocaine products at retail level, 2006
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-7. Purity of cocaine products at retail level, 2006
Part (iii) Sampling frame / Type of study
|
table |
| PPP |
Table PPP-8. Purity of synthetic drugs at retail level, 2006
Part (i) Minimum, maximum, mean and modal (typical) purity recorded
|
table |
| PPP |
Table PPP-8. Purity of synthetic drugs at retail level, 2006
Part (ii) Sources of information
|
table |
| PPP |
Table PPP-8. Purity of synthetic drugs at retail level, 2006
Part (iii) Sampling frame / Type of study
|
table |
| PPP |
Figure PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2001–06
|
figure |
| INF |
Figure INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million, 1996 to 2006
|
figure |
| INF |
Figure INF-2. HIV infections newly diagnosed in injecting drug users, by year of report, by country, cases per million, 1996–2006
|
figure |
| INF |
Figure INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage
Part (i) All injecting drug users, 2005 and 2006
|
figure |
| INF |
Figure INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage
Part (ii) Young injecting drug users (under age 25), 2005 to 2006
|
figure |
| INF |
Figure INF-6. Estimated HCV antibody prevalence among injecting drug users — studies with national and subnational coverage
Part (i) Sample estimates, 2005 to 2006
|
figure |
| INF |
Figure INF-6. Estimated HCV antibody prevalence among injecting drug users — studies with national and subnational coverage
Part (ii) Estimates for the sub-sample of young injecting drug users (under age 25), 2005 to 2006
|
figure |
| INF |
Figure INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2005 to 2006, where data are available
Part (i) Percentage positive for ever infected (aHBc)
|
figure |
| INF |
Figure INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2005 to 2006, where data are available
Part (ii) Percentage positive for current infection (HBsAg)
|
figure |
| EYE |
Figure EYE-3. Comparison of frequency of drug use by substance in recreational settings: summary of comparable surveys of 9 European cities in 2006
|
figure |
| EYE |
Figure EYE-5. Changes between 2001/02 and 2005/06 in prevalence of ever in lifetime cannabis use among school students aged 15–16
|
figure |
| PDU |
Table PDU-104. Trends in injecting drug use - percentage currently injecting among all clients entering treatment for primary drug heroin, 2001 to 2006
|
table |
| TDI |
Figure TDI-7. New outpatient clients injecting opioid as primary drug from 2003 to 2006 in 13 countries supplying data
|
figure |
